Alamar Biosciences
About
Alamar Biosciences NULISA technology enables unprecedented attomolar detection of protein biomarkers in a diversity of matrices, enabling early disease detection in neurodegenerative, inflammatory conditions. The NULISA technology is ideal for the translational workflow from preclinics to clinical research, enabling wide detection of biomarkers and focus on the most important ones as endpoints.
Disease Area
CancerInflammation / Autoimmune DiseasesCardiovascular DiseasesInfectious DiseasesMetabolic DiseasesNeurological Diseases
Biomedical Research, Medicine, Human Health
Biomarker DiscoveryEarly DetectionTherapy MonitoringClinical Research, Trials
Technology
Other
Representatives
Regional Business Manager
Alamar Biosciences